EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Oryzon Genomics S.A (0RDB) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Oryzon Genomics S.A €2.12, price €2.72, upside -22.1%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · Home Spain · ISIN ES0167733015

OG Thin data Aug 5, 2026

Oryzon Genomics S.A

0RDB · LSE

Weak valuationQuality is weak on top of the rich price.

!Fair value €2.12 · Overvalued (−22.1%)
!Quality 20/100
!Weak Growth (revenue 5y −7.9 %/yr)
!Loss-making · -20.4% net margin (TTM)
!negative free cash flow
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.43 €2.67 Fair Value €2.12 Dec 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Aug 5, 2026.

How to read this chart

10‑month range €2.67 – €3.43 · fair‑value band €1.58 – €3.17 · the €2.72 price screens above the €2.12 fair value. As of Aug 5, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.

Show more

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.

Stock analysis

Oryzon Genomics S.A (0RDB) currently trades at €2.72, while our model-based Fair Value estimate is €2.12, 22.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 82/100, which puts the evidence level at low.

Scenario range: €1.58 (bear) to €3.17 (bull), the price of €2.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Oryzon Genomics S.A reported revenue of $7.6M in FY2024 versus $11.6M in FY2020, a compound −10.0%/yr. Reported net income was −$3.1M in FY2025.

Key figures

Market cap €202M · P/S ratio 8.21 · EPS (TTM) €−0.0880 · Net margin −20.4% · Return on equity −2.5% · Return on assets (EBIT) −5.1% · Operating margin −75.3% · Revenue (TTM) $12.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −22%, 0RDB screens richer than that median.

Fair Value models

Bear €1.58 Fair Value €2.12 Bull €3.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) €1.64 €2.20 €3.29 51
All 1 models by family
Asset-Based
NCAV (Graham) €1.64 €2.20 €3.29 51

Open the full fair value analysis →

Notify me when 0RDB reaches fair value

Put 0RDB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 25 · Market factors (momentum, volatility) 43

Profitability 4
Margins and returns on capital today
Quality Growth 14
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 47
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 36
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−51.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.3% (2019) → −60.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0RDB screens overvalued: fair value 22% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oryzon Genomics S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oryzon Genomics S.A · Fair Value
€2.12 −22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Oryzon Genomics S.A Fair Value". https://www.fairvalue-calculator.com/stock/0RDB

Frequently asked questions

Is Oryzon Genomics S.A (0RDB) overvalued or undervalued?
As of Aug 5, 2026, our model estimates a fair value of €2.12 versus a price of €2.72, about −22% upside (overvalued).
What is the fair value of 0RDB?
Our model-based fair value for Oryzon Genomics S.A is €2.12 (as of Aug 5, 2026), built from audited fundamentals. The current price: €2.72.
What is the quality score of 0RDB?
Oryzon Genomics S.A has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oryzon Genomics S.A (0RDB)?
Our model-based price target is the fair value of €2.12 (as of Aug 5, 2026) from 1 valuation models. Cautious scenario €1.58, optimistic scenario €3.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Oryzon Genomics S.A stock forecast for 2026?
Our models put fair value at €2.12, about −22% upside versus a price of €2.72 (overvalued). Cautious scenario €1.58, optimistic scenario €3.17. The calculation is refreshed regularly with new filings.
What is the revenue of Oryzon Genomics S.A (0RDB)?
Oryzon Genomics S.A reported trailing-twelve-month revenue of about $12.6M (latest available figure, as of Aug 5, 2026).
What is the intrinsic value of Oryzon Genomics S.A (0RDB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oryzon Genomics S.A it is €2.12 per share (as of Aug 5, 2026), against a price of €2.72. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oryzon Genomics S.A stock overvalued or undervalued in 2026?
As of Aug 5, 2026, 0RDB trades above its calculated fair value: price €2.72, fair value €2.12, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RDB?
No. The price is what the market pays today (€2.72); the fair value is what the company's own numbers justify (€2.12). For Oryzon Genomics S.A the two are €0.6000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oryzon Genomics S.A worth?
The market values Oryzon Genomics S.A at about €202M (market capitalisation, as of Aug 5, 2026). Per share that is €2.72; our models calculate a fair value of €2.12 per share.
What do the bullish and bearish scenarios say about 0RDB?
Our models span a range for Oryzon Genomics S.A: cautious scenario €1.58, base €2.12, optimistic €3.17 per share (as of Aug 5, 2026, price €2.72). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Oryzon Genomics S.A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oryzon Genomics S.A stock attractive at the current price?
The data as of Aug 5, 2026: price €2.72, calculated fair value €2.12 (−22%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RDB calculated?
We run Oryzon Genomics S.A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €2.12, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Oryzon Genomics S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oryzon Genomics S.A (0RDB)?
The closing price on Oct 2, 2026 was €2.72. Our model-based fair value is €2.12, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oryzon Genomics S.A right now?
Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (€1.58 to €3.17) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Oryzon Genomics S.A

How large is the market capitalisation of Oryzon Genomics S.A (0RDB)?
The market capitalisation of Oryzon Genomics S.A is €202M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oryzon Genomics S.A (0RDB)?
The price-to-sales ratio of Oryzon Genomics S.A is 8.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oryzon Genomics S.A (0RDB)?
Earnings per share at Oryzon Genomics S.A are €−0.0880. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oryzon Genomics S.A (0RDB)?
The net margin of Oryzon Genomics S.A is −20.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oryzon Genomics S.A (0RDB)?
The return on equity (ROE) of Oryzon Genomics S.A is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oryzon Genomics S.A (0RDB)?
On an EBIT basis the return on assets of Oryzon Genomics S.A is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oryzon Genomics S.A (0RDB)?
The operating margin of Oryzon Genomics S.A is −75.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oryzon Genomics S.A (0RDB)?
Revenue at Oryzon Genomics S.A is growing +48.6% versus a year earlier (3y avg −14.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Oryzon Genomics S.A (0RDB) generate?
The free cash flow of Oryzon Genomics S.A is −$2.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oryzon Genomics S.A (0RDB) hold?
Oryzon Genomics S.A holds more cash than debt, $19.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.